Pharma News
Teva and Takeda establish ‘Teva Takeda Yakuhin’ in Japan
Israeli generics giant Teva Pharmaceutical Industries (Teva) and Japan-based Takeda Pharmaceutical Company (Takeda) have formed a joint company ‘Teva Takeda Yakuhin’ to produce and sell off-patented medicines in Japan.
SGS and DiscoverX to collaborate on bioassays for biosimilars
Contract solutions provider SGS announced on 30 March 2016 that it had entered into a collaboration with innovative life science company DiscoverX.
Dr Reddy’s and TRPharm collaborate on biosimilars in Turkey
Generics giant Dr Reddy’s Laboratories and Turkish pharma start-up firm TRPharm announced on 10 March 2016 that they had entered into a strategic collaboration agreement for a portfolio of biosimilars in Turkey.
Partnership between PlantForm and Guelph University for biosimilar trastuzumab
Canada-based PlantForm Corporation (PlantForm) announced on 3 March 2016 that it had been awarded a Collaborative Research and Development Grant from the Natural Sciences and Engineering Research Council of Canada (NSERC).
Oncobiologics and Premier make biosimilars deal
US biotechnology company Oncobiologics and healthcare performance improvement alliance Premier announced on 3 March 2016 that they had entered into a collaboration aimed at increasing the use of biosimilars.
Strides Shasun acquires Australian and Kenyan generics makers
India-based generics manufacturer Strides Shasun has increased its generics portfolio and presence across the globe with two new acquisitions.
Mylan to acquire Swedish drugmaker Meda
US generics manufacturer Mylan announced on 10 February 2016 that it had made a deal worth US$9.9 billion (for shares and debt) to buy Swedish drugmaker Meda.
Fuji Pharma gains rights to darbepoetin alfa biosimilar in Japan
Japan-based Fuji Pharma announced on 5 January 2016 that it had signed a license agreement with Chong Kun Dang Pharmaceutical (CKD Pharma). Under the agreement, Fuji Pharma has the exclusive rights in Japan for the development, manufacture, distribution and sale of CKD Pharma’s darbepoetin alfa biosimilar (CKD‑11101).
Mylan and Momenta to jointly develop and commercialize six biosimilar products
Mylan NV has agreed an exclusive global collaboration with Momenta Pharmaceuticals Inc (Momenta) to develop, manufacture and commercialize six of Momenta's biosimilar candidates.
Eisai acquires Chinese generics maker
Japanese pharmaceutical company Eisai announced on 28 December 2015 that it had acquired Chinese generics maker Liaoning TianYi Biological Pharmaceutical.
